Preclinical studies involving resistance to antiangiogenic therapies

(Bentham Science Publishers) New blood vessel growth, or angiogenesis, is critical for cancer to grow and spread throughout the body. Drugs that target vascular endothelial growth factor -- a key driver of angiogenesis -- are now approved for the treatment of several metastatic cancers. However, not all patients respond and many more eventually become resistant after initial treatment benefits.